Navigation Links
Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Date:8/7/2008

SAN RAMON, Calif., Aug. 7 /PRNewswire/ -- Odyssey Thera, Inc. announced that it has received a milestone payment from Pfizer Inc, following Pfizer's decision to progress a discovery stage drug candidate into pre-clinical development. The drug candidate was extensively studied by Odyssey Thera as part of the ongoing collaboration with Pfizer.

"We are very pleased with the progress of the collaboration with Pfizer," said John K. Westwick, Ph.D., Odyssey Thera's President and CEO. "Progress on this and other discovery programs with Pfizer demonstrates the power of our unique cellular analysis platform to improve knowledge of drug mechanisms and selectivity."

In August 2006, Odyssey Thera announced its third alliance with Pfizer. Under the terms of the multi-year agreement, Odyssey Thera is collaborating on multiple Pfizer drug discovery projects, and has received upfront payments, research and capital expenditure funding, and previous success-based milestones. The achievement of this milestone announced today is the Company's first such milestone to be earned for contributing to the advancement of a drug candidate.

About Odyssey Thera, Inc.

Odyssey Thera's patented technology measures disease-relevant pathway activity within living human cells. Rapid identification of on-target and off-pathway activities of lead compounds enables selection of drug candidates with favorable safety and selectivity profiles. Odyssey is leveraging its proprietary drug discovery and development platform for internal programs and for premier pharmaceutical company partners.

To learn more about Odyssey Thera, please visit http://www.odysseythera.com


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
2. Odyssey Thera Granted U.S. Patent for Animal Imaging
3. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
4. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
5. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
6. CV Therapeutics Reports 2008 Second Quarter Financial Results
7. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
8. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
9. Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement
10. United Therapeutics Reports Second Quarter 2008 Financial Results
11. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...G VALLEY, Calif., Nov. 6 Calbiotec... Small Business Innovative Research (SBIR) Phase I...terial command. Under terms of the agreement, Calb...s) for the diagnosis of Dengue virus. ,, Den...sents a major threat to military forces deployed t...
(Date:11/5/2009)...ERSBURG, Md., Nov. 5 Gen...ancial results for the third quarter ended Septemb...llion ($0.04 per share) for the three months ended... million ($0.08 per share) in the comparable quart..., 2009, GenVec,s net loss was $14.1 million ($0.15...
(Date:11/5/2009)...rence Call on Thursday, November 5, 2009 at 4:30 p...Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmace...AQ: OGXI ) today reported unaudited financial res...eptember 30, 2009 and reviewed the Company,s highl...lowing consolidated results reflect the operations...
(Date:11/5/2009)...IEGO, CA, November 5, 2009 /PRNewswire-FirstCall/ ...ed on using proprietary taste receptor-based techn...he food, beverage, and ingredient supply industrie...financial results for the third quarter ended Sept...e third quarter of 2009, compared to $4.0 million ...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...nference Call Tomorrow (Tuesday) at 8:30 am EDT to... Valley Cottage, NEW YORK, September 10 XTL,Biop...E: XTL) today announced,the initiation of a Phase ... norepinephrine reuptake inhibitor (SNRI) - for th...ine is being developed for the treatment of diabet...
...ltern, a leading global research,organization, is ...,Chiltern,s Country Manager for the Czech Republic...e year award. The award ceremony was held in,Londo...om amongst his peers by a panel of judges who,revi...ccessful conclusion,of clinical trials. The judgin...
Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
Other Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
(Date:11/9/2009)...s inspired a 3.2m, three-year research project tha...security, energy and the environment. The Universi...QinetiQ have just signed a collaborative contract ...g physical sciences research. , Over the next t...y of Exeter and QinetiQ will work together to deve...
(Date:11/9/2009)...09 / b3c newswire / - Today, TNO, a Dutch contr...erican organization for contract research and cons... letter of intent with regard to TNOs dynamic in ...intent proposes a collaboration in which Seventh W...ion in North America. The TIM systems will be used...
(Date:11/9/2009)...leaders from around the world will gather in Bosto...ar Targets and Cancer Therapeutics International C...mation on important cancer therapies in developmen...it effectively we need a greater understanding of ...el," said Lewis Cantley, Ph.D., director of the ca...
Breaking Biology News(10 mins):£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Exponent to Announce Second Quarter 2009 Results 51709 1Elton John Billy Crystal Tony Bennett and Gladys Knight Help Starkey Hearing Foundation Raise More than 245 Million at Annual Fundraiser 51705 1Elton John Billy Crystal Tony Bennett and Gladys Knight Help Starkey Hearing Foundation Raise More than 245 Million at Annual Fundraiser 51705 2Elton John Billy Crystal Tony Bennett and Gladys Knight Help Starkey Hearing Foundation Raise More than 245 Million at Annual Fundraiser 51705 3Reminders Boost Mammography Appointments 51703 1Reminders Boost Mammography Appointments 51703 2
...ls have been little more than electronic versions ...the launch of PLoS ONE, which publishes primary re...pre- and post-publication peer review to maximize ...is published by the Public Library of Science (PLo...e the world,s scientific and medical literature a ...
...Many of them had narrow, pointed teeth, which were...wing them. But how did they then grind their food?... they were helped by stones which they swallowed. ...nd of ,gastric mill,. But this assumption does not...ties of Bonn and Tübingen have now proved. Their r...
... based on a combination of satellite data, compute...moke from Alaskan and Canadian forest fires as muc... away in Houston during a two-day period in July 2...in the Journal of Geophysical Research, offers sci...effects from pollutants generated thousands of mil...
Other Biology News:PLoS ONE is launched by the Public Library of Science 2PLoS ONE is launched by the Public Library of Science 3Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3NASA study: Alaskan fires affected Houston air quality in 2004 2NASA study: Alaskan fires affected Houston air quality in 2004 3
Fingerprinting II Database Sharing Tools from Bio-Rad
Fingerprinting II Identification and Library Manager from Bio-Rad
DNA Engine Opticon 2 Continuous Fluorescence Detection System from Bio-Rad
...High Quality, Functionally-Validated, Ion Channel ...ng a critical role in nerve and muscle function an...d the heart. Drugs that modulate ion channels have...europathic pain, cardiac arrhythmia, hypertension,...
Biology Products: